Skip to content

Inspection Record

Kaysersberg Pharmaceuticals SAS — FDA 483 Findings

US FDAInspected 2016-07-19Published 2026-10-23 8 findingsProcess validationLaboratory and QC controlsDeviation, CAPA, and investigationEquipment and facilityAseptic processing and sterility assurance

Inspectors Michael A CharlesThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Process validation

Written production and process control procedures are not documented at the time of performance.

2Laboratory and QC controls

Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that in-process materials conform to appropriate standards of identity, strength, quality and purity.

3Deviation, CAPA, and investigation

Written records of investigations into unexplained discrepancies do not always include the conclusions and follow-up.

4Process validation

Control procedures are not established which monitor the output and validate the performance of those manufacturing processes that may be responsible for causing variability in the characteristics of in- process material and the drug product.

5Equipment and facility

Routine calibration of mechanical equipment is not performed according to a written program designed to assure proper performance.

6Equipment and facility

Written procedures for cleaning and maintenance fail to include description in sufficient detail of methods, equipment and materials used and parameters relevant to the operation.

7Aseptic processing and sterility assurance

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

8Equipment and facility

There is a lack of written procedures describing in sufficient detail the methods, equipment and materials to be used for sanitation.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-23. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

Kaysersberg Pharmaceuticals SAS company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.